Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis

  • Published: May 14, 2020
  • Authors:Daniel A. PfefferID1*, Benedikt LeyID1, Rosalind E. HowesID2,3, Patrick AduID4, Mohammad Shafiul AlamID5, Pooja BansilID6, Yap Boum, IIID7,8, Marcelo BritoID9, Pimlak CharoenkwanID10, Archie Clements11,12, Liwang CuiID13, Zeshuai DengID14, Ochaka Julie Egesie15, Fe Esperanza EspinoID16, Michael E. von FrickenID17, Muzamil Mahdi Abdel HamidID18, Yongshu He14, Gisela Henriques19, Wasif Ali Khan5, Nimol KhimID20, Saorin Kim20, Marcus LacerdaID9, Chanthap Lon21, Asrat Hailu Mekuria22, Didier MenardID23, Wuelton MonteiroID9, Franc¬łois NostenID24,25, Nwe Nwe OoID26, Sampa PalID6, Duangdao PalasuwanID27, Sunil Parikh28, Ayodhia Pitaloka PasaribuID29, Jeanne Rini PoespoprodjoID30, David J. PriceID31,32, Arantxa Roca-FeltrerID33, Michelle E. Roh34, David L. Saunders21,35,36, Michele D. SpringID21, Inge Sutanto37, Kamala LeyThriemerID1, Thomas A. Weppelmann38, Lorenz von SeidleinID24,39, Ari Winasti SatyagrahaID40, Germana BanconeID24,25, Gonzalo J. DomingoID6, Ric N. PriceID1,25,39


The radical cure of Plasmodium vivax and P. ovale requires treatment with primaquine or tafenoquine to clear dormant liver stages. Either drug can induce haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, necessitating screening. The reference diagnostic method for G6PD activity is ultraviolet (UV) spectrophotometry; however, a universal G6PD activity threshold above which these drugs can be safely administered is not yet defined. Our study aimed to quantify assay-based variation in G6PD spectrophotometry and to explore the diagnostic implications of applying a universal threshold.